Akèy › Kansè lestomak › Oregon › Portland
Etid klinik pou Kansè lestomak nan Portland, OR
13 etid pou Kansè lestomak ap chèche patisipan nan sit nan ak bò kote Portland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi lwen
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Ap rekriteFaz 1
- Site 02, Portland
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Ap rekriteFaz 2/3
- Northwest Cancer Specialists, P.C., Portland
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Ap rekriteFaz 3
- Oregon Health and Science University, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Providence Portland Medical Center, Portland
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Ap rekriteFaz 3
- Research Site, Portland
- Research Site, Portland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Providence Cancer Institute, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Providence Cancer Institute, Portland
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Ap rekriteFaz 3
- Providence Portland Medical Center, Portland
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #121, Portland
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- ak 1 plis
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Oregon Health Sciences University, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Portland
Etid Kansè lestomak nan lòt vil
- Houston, TX42 etid
- Boston, MA32 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Baldwin Park, CA22 etid
- Los Angeles, CA22 etid
- Arlington, VA20 etid
- Dallas, TX19 etid
- San Antonio, TX19 etid
- Grand Rapids, MI18 etid
- St. Louis, MO18 etid
- Washington, DC16 etid
Lòt etid nan Portland
- Kansè Poumon ki pa ti selil46 etid
- Kansè (tout kalite)34 etid
- Kansè nan tete33 etid
- Kansè pwostat33 etid
- Kansè Metastatik29 etid
- Kansè kolorektal28 etid
- Kansè ovè27 etid
- Kansè poumon26 etid
- Leksemi mieloïd egi25 etid
- Kansè Endomèt24 etid
- Karsinòm selil skuamèz tèt ak kou19 etid
- Kansè pankreyas19 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.